ApoA-IMilano from structure to clinical application

Annals of Medicine

Volumn 40, Issue SUPPL. 1, 2008, Pages 48-56

  Eberini, Ivano ^a   Gianazza, Elisabetta ^a   Calabresi, Laura ^a,b   Sirtori, Cesare R ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Animal model; Apolipoprotein A IMilano; Cardiovascular risk; HDL therapy; High density lipoprotein (HDL); IVUS; Liposome; Phospholipid; Synthetic HDL; Transgenic mouse

Indexed keywords

ABC TRANSPORTER; APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; PLACEBO;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENTIATION; GENE THERAPY; HEART PROTECTION; HUMAN; HYPERLIPIDEMIA; MONOTHERAPY; NONHUMAN; PREVENTION AND CONTROL; PRIORITY JOURNAL; VASCULAR DISEASE;

EID: 38849206254     PISSN: 07853890     EISSN: 16512219     Source Type: Journal    
DOI: 10.1080/07853890701687193     Document Type: Conference Paper

References (51)

1. M apoprotein: Decreased high density lipoprotein levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest. 1980;66:892-900.
2. Milano variant. J Biol Chem. 1982;257:9926-30.
3. Milano dimer. Biochemistry. 1999;38:16307-14.
4. M apoprotein: Identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet. 1985;37:1083-97.
5. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999;353:89-92.
6. Milano mutant: The Limone sul Garda study. Circulation. 2001;103:1949-54.
7. Milano, associated with familial hypo-α-lipoproteinemia. J Clin Invest. 1993;91:1445-52.
8. Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA. 2003;290:2322-4.
9. Milano carriers and transgenic mice. Arterioscler Thromb Vasc Biol. 1999;19:1257-62.
10. Favari E, Gomaraschi M, Zanotti I, Bernini F, Lee-Rueckert M, Kovanen PT, et al. A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-IMilano dimer effectively promotes ATP-binding Cassette A1-mediated cell cholesterol efflux. J Biol Chem. 2007;282:5125-32.
11. Oram JF, Lawn RM, Garvin MR, Wade DP. ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J Biol Chem. 2000;275:34508-11.
12. Weibel GL, Alexander ET, Joshi MR, Rader DJ, Lund-Katz S, Phillips MC, et al. Wild-type ApoA-I and the Milano variant have similar abilities to stimulate cellular lipid mobilization and efflux. Arterioscler Thromb Vasc Biol. 2007;27:2022-9.
13. Rader DJ. High-density lipoproteins as an emerging therapeutic target for atherosclerosis. JAMA. 2003;290:2322-4.
14. Kunitake ST, Chen GC, Kung SF, Schilling JW, Hardman DA, Kane JP. Pre-β high density lipoprotein: Unique disposition of apolipoprotein A-I increases susceptibility to proteolysis. Arteriosclerosis. 1990;10:25-30.
15. Eberini I, Calabresi L, Wait R, Tedeschi G, Pirillo A, Puglisi L, et al. Macrophage metalloproteinases degrade HDL-associated apoA-I at both the N- and the C-terminus. Biochem J. 2002;362:627-34.
16. Lee M, Kovanen PT, Tedeschi G, Oungre E, Franceschini G, Calabresi L. Apolipoprotein composition and particle size affect HDL degradation by chymase: Effect on cellular cholesterol efflux. J Lipid Res. 2003;44:539-46.
17. Caslake MJ, Farish E, Shepherd J. Metabolism of apolipoprotein A-I in healthy young adults. Metabolism. 1978;27:437-47.
18. Nair PN, Sjogren U, Sundqvist G. Cholesterol crystals as an etiological factor in non-resolving chronic inflammation: An experimental study in guinea pigs. Eur J Oral Sci. 1998;106:644-50.
19. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 1997;336:1276-82.
20. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: A comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20:1262-75.
21. Lindstedt L, Saarinen J, Kalkkinen N, Welgus H, Kovanen PT. Matrix metalloproteinases-3, -7, and -12, but not -9, reduce high density lipoprotein-induced cholesterol efflux from human macrophage foam cells by truncation of the carboxyl terminus of apolipoprotein A-I. Parallel losses of pre-beta particles and the high affinity component of efflux. J Biol Chem. 1999;274:22627-34.
22. Milano-apoA-II supports its peculiar susceptibility to proteolysis. Biophys J. 2006;91:3043-9.
23. Minnich A, Collet X, Roghani A, Cladaras C, Hamilton RL, Fielding CJ, et al. Site-directed mutagenesis and structure-function analysis of the human apolipoprotein A-I. Relation between lecithin-cholesterol acyltransferase activation and lipid binding. J Biol Chem. 1992;267:16553-60.
24. Sorci-Thomas M, Kearns MW, Lee JP. Apolipoprotein A-I domains involved in lecithin-cholesterol acyltransferase activation. Structure:function relationships. J Biol Chem. 1993;268:21403-9.
25. Milano dimer: The introduction of an interchain disulfide bridge remarkably alters the physicochemical properties of apolipoprotein A-I. J Biol Chem. 1994;269:32168-74.
26. Holvoet P, Zhao Z, Vanloo B, Vos R, Deridder E, Dhoest A, et al. Phospholipid binding and lecithin-cholesterol acyltransferase activation properties of apolipoprotein A-I mutants. Biochemistry. 1995;34:13334-42.
27. Schmidt HH, Remaley AT, Stonik JA, Ronan R, Wellmann A, Thomas F, et al. Carboxyl-terminal domain truncation alters apolipoprotein A-I in vivo catabolism. J Biol Chem. 1995;270:5469-75.
28. Davidson WS, Hazlett T, Mantulin WW, Jonas A. The role of apolipoprotein A-I domains in lipid binding. Proc Natl Acad Sci U S A. 1996;93:13605-10.
29. Rye KA, Barter PJ. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol. 2004;24:421-8.
30. Franceschini G, Werba JP, Calabresi L. Drug control of reverse cholesterol transport. Pharmacol Ther. 1994;61:289-324.
31. Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation. 1994;90:1935-41.
32. Milano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits. Circ Res. 1995;76:405-11.
33. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 1995;15:1987-94.
34. Barter PJ. Inhibition of endothelial cell adhesion molecule expression by high density lipoproteins. Clin Exp Pharmacol Physiol. 1997;24:286-7.
35. Dimayuga P, Zhu J, Oguchi S, Chyu KY, Xu XO, Yano J, et al. Reconstituted HDL containing human apolipoprotein A-I reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. Biochem Biophys Res Commun. 1999;264:465-8.
36. Milano on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation. 1998;97:780-5.
37. Milano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice. Potential implications for acute plaque stabilization. Circulation. 2001;103:3047-50.
38. Chiesa G, Di Mario C, Colombo N, Vignati L, Marchesi M, Monteggia E, et al. Development of a lipid-rich, soft plaque in rabbits, monitored by histology and intravascular ultrasound. Atherosclerosis. 2001;156:277-87.
39. Di Mario C, The SH, Madretsma S, van Suylen RJ, Wilson RA, Bom N, et al. Detection and characterization of vascular lesions by intravascular ultrasound: An in vitro study correlated with histology. J Am Soc Echocardiogr. 1992;5:135-46.
40. Milano infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res. 2002;90:974-80.
41. Milano and regression of atherosclerosis. JAMA. 2004;291:1319; author reply 1320.
42. Carlson LA. Effect of a single infusion of recombinant human proapolipoprotein A-I liposomes (synthetic HDL) on plasma lipoproteins in patients with low high density lipoprotein cholesterol. Nutr Metab Cardiovasc Dis. 1995;5:85-91.
43. Eriksson M, Carlson LA, Miettinen TA, Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation. 1999;100:594-8.
44. Nanjee MN, Doran JE, Lerch PG, Miller NE. Acute effects of intravenous infusion of ApoAI/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler Thromb Vasc Biol. 1999;19:979-89.
45. Nanjee MN, Cooke CJ, Garvin R, Semeria F, Lewis G, Olszewski WL, et al. Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res. 2001;42:1586-93.
46. Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG, Binggeli C, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105:1399-402.
47. Bisoendial RJ, Hovingh GK, de Groot E, Kastelein JJ, Lansberg PJ, Stroes ES. Measurement of subclinical atherosclerosis: Beyond risk factor assessment. Curr Opin Lipidol. 2002;13:595-603.
48. Milano. J Am Coll Cardiol. 2006;47:992-7.
49. Baldassarre D, Amato M, Bondioli A, Sirtori CR, Tremoli E. Carotid artery intima-media thickness measured by ultrasonography in normal clinical practice correlates well with atherosclerosis risk factors. Stroke. 2000;31:2426-30.
50. Tardif JC, Gregoire J, L'Allier PL, Ibrahim R, Lesperance J, Heinonen TM, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: A randomized controlled trial. JAMA. 2007;297:1675-82.
51. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. New Engl J Med. 2001;345:1583-92.